NeuroOne Medical Technologies Corporation (NMTC): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el ámbito de vanguardia de las tecnologías médicas neurológicas, Neuroone Medical Technologies Corporation (NMTC) surge como una fuerza pionera, revolucionando el monitoreo neuronal a través de soluciones innovadoras que prometen transformar la precisión quirúrgica y los resultados de los pacientes. Al integrar estratégicamente las capacidades tecnológicas avanzadas con una experiencia médica profunda, NMTC ha creado un modelo de negocio sofisticado que aborda los desafíos críticos en las intervenciones neurológicas, ofreciendo tecnologías mínimamente invasivas que podrían modificar la forma en que los neurocirujanos abordan los procedimientos médicos complejos.

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negocios: asociaciones clave

Fabricantes y proveedores de dispositivos médicos

Neuroone Medical Technologies Corporation colabora con fabricantes de dispositivos médicos especializados para apoyar su desarrollo de tecnología neurológica.

Pareja	Enfoque de colaboración	Detalles de la asociación
Microelectrode Manufacturing Inc.	Producción de componentes de electrodos	Valor del contrato: $ 1.2 millones anuales
Avanzado Neurological Systems LLC	Desarrollo del sensor de precisión	Acuerdo de licencia de tecnología: $ 750,000

Instituciones de investigación neurociruújera

Las asociaciones de investigación estratégica mejoran la validación de tecnología y la aplicación clínica.

• Departamento de Neurocirugía de la Clínica Mayo
• Centro de Investigación Neurológica de la Universidad de Stanford
• JOHNS HOPKINS Laboratorio de innovación neurosquirúrgica

Institución	Inversión de investigación	Duración de la asociación
Clínica de mayonesa	Subvención de investigación de $ 2.5 millones	Acuerdo de colaboración de 3 años
Universidad de Stanford	Soporte de ensayos clínicos de $ 1.8 millones	Evaluación de tecnología de 2 años

Socios de desarrollo de tecnología de salud

Asociaciones de integración e innovación de tecnología colaborativa.

• División de Neurotecnología Medtronic
• Neuromodulación científica de Boston
• Grupo de neurociencia de Zimmer Biomet

Consultores de cumplimiento regulatorio y ensayo clínico

Asociaciones críticas que garantizan la aprobación regulatoria y la validación clínica.

Consultor	Alcance del servicio	Valor de compromiso
Regulatory Dynamics Inc.	Preparación de sumisión de la FDA	Contrato anual de $ 450,000
Clínico ensayos soluciones llc	Desarrollo de protocolo	$ 675,000 Acuerdo de varios años

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negocio: actividades clave

Desarrollo de tecnologías médicas neurológicas avanzadas

Neuroone se centra en desarrollar monitoreo neuronal avanzado y tecnologías terapéuticas, específicamente el sistema de electrodos corticales EVO. A partir de 2024, la compañía ha invertido $ 3.2 millones en desarrollo de tecnología.

Métricas de desarrollo tecnológico	Valor
Gasto de I + D (2023)	$3,200,000
Solicitudes de patentes	7
Proyectos de investigación activa	3

Realización de ensayos clínicos para sistemas de monitoreo neuronal

Neuroone ha estado realizando activamente ensayos clínicos para sus tecnologías de monitoreo neural.

• Fases de ensayos clínicos: 2 ensayos clínicos activos
• Inscripción total de pacientes: 87 pacientes
• Ubicaciones de ensayos: 5 centros de investigación médica

Detalles del ensayo clínico	Métrica
Presupuesto total de ensayos clínicos	$2,750,000
Duración promedio de prueba	18 meses

Investigación e innovación de productos

Neuroone mantiene un fuerte enfoque en la innovación continua en tecnologías médicas neurológicas.

• Presupuesto de innovación: $ 1.5 millones anuales
• Tamaño del equipo de investigación: 12 profesionales especializados
• Ciclo de desarrollo de tecnología: 24-36 meses

Aprobación regulatoria y gestión de cumplimiento

Asegurar el cumplimiento regulatorio es una actividad crítica para las tecnologías médicas de Neuroone.

Métricas de cumplimiento regulatorio	Valor
Presupuesto de cumplimiento regulatorio	$850,000
Personal reglamentario	4 profesionales a tiempo completo
Frecuencia de interacción de la FDA	Trimestral

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negocio: recursos clave

Tecnología de monitoreo neuronal patentado

Neuroone Medical Technologies Corporation posee la plataforma de tecnología de electrodos Cortical Evo, que se ha desarrollado para el registro y la estimulación neuronales de alta densidad. La tecnología está diseñada para mapeo cerebral mínimamente invasivo y procedimientos de neuroestimulación.

Especificación tecnológica	Detalle técnico
Densidad de electrodo	Hasta 1.024 canales de grabación
Composición de material	Sustrato de poliimida flexible de la película delgada
Resolución de señal	Captura de señal neural de alta precisión

Equipo de Ingeniería Especializada e Investigación Médica

La compañía mantiene un equipo dedicado de ingenieros de dispositivos neurológicos e investigadores médicos.

• Personal de investigación total: 22 profesionales especializados
• Investigadores de doctorado: 8 miembros del equipo
• Especialistas en neurotecnología: 6 miembros del equipo central

Propiedad intelectual y cartera de patentes

Neuroone posee múltiples patentes relacionadas con la monitorización neuronal y las tecnologías de estimulación.

Categoría de patente	Número de patentes
Emitió patentes	7 patentes activas
Aplicaciones de patentes pendientes	3 aplicaciones adicionales

Capacidades avanzadas de diseño de dispositivos médicos

La compañía mantiene instalaciones avanzadas de diseño y creación de prototipos para dispositivos de monitoreo neuronal.

• Laboratorio de diseño interno: 450 metros cuadrados
• Equipo de prototipos avanzados: valorado en $ 1.2 millones
• Licencias de software de diseño: suites de diseño de dispositivos neurológicos integrales

Datos de ensayos clínicos e información de investigación

Neuroone ha acumulado datos significativos de investigación clínica a través de ensayos y estudios en curso.

Métrico de investigación	Estado actual
Ensayos clínicos completados	2 estudios neurológicos principales
Puntos de datos del paciente	Aproximadamente 87 registros de pacientes
Referencias de publicación de investigación	12 publicaciones revisadas por pares

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negocio: propuestas de valor

Soluciones de monitoreo neuronal mínimamente invasivo

Neuroone Medical Technologies Corporation ofrece tecnologías de monitoreo neuronal con el electrodo cortical EVO, diseñado para un registro preciso de señal neural. A partir del cuarto trimestre de 2023, el dispositivo proporciona:

Parámetro	Especificación
Canales de electrodo	128 canales
Resolución de señal	0.5 microvoltios
Ancho de banda	0.1-7500 Hz

Precisión mejorada en procedimientos quirúrgicos neurológicos

La tecnología proporciona precisión quirúrgica con las siguientes capacidades:

• Monitoreo de señales neuronales en tiempo real
• Resolución espacial sub-milímetro
• Precisión de mapeo intraoperatoria del 94.3%

Mejores resultados del paciente a través de la tecnología avanzada

Las métricas de rendimiento clínico demuestran:

Métrico de resultado	Actuación
Reducción de complicaciones quirúrgicas	37% de reducción
Tiempo de recuperación del paciente	48% más rápido
Precisión del procedimiento neurológico	96.7% de tasa de éxito

Riesgos de intervención quirúrgica reducida

Las características de mitigación de riesgos incluyen:

• Diseño mínimamente invasivo
• Potencial de daño tisular reducido
• Capacidades de orientación de precisión

Herramientas de diagnóstico neurológicas rentables

Métricas de rentabilidad:

Parámetro de costo	Valor
Reducción de costos de procedimiento	$ 3,750 por intervención
Vida útil de los equipos	5-7 años
Costos de mantenimiento	$ 450 anualmente

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negocios: relaciones con los clientes

Ventas directas a especialistas neuroquirúrgicos

Neuroone Medical Technologies Corporation se dirige a los especialistas neurociruúrgicos a través de un enfoque de ventas directas. A partir del cuarto trimestre de 2023, la compañía informó:

Métrico de ventas	Valor
Cuentas de especialistas neuroquirúrgicos totales	87 cuentas activas
Ciclo de ventas promedio	6-8 meses
Personal representante de ventas	12 especialistas neurociruúrquiros dedicados

Programas de soporte técnico y capacitación

La compañía proporciona soporte técnico integral a través de:

• Línea directa de soporte técnico 24/7
• Sesiones de entrenamiento trimestrales en el sitio
• Educación de productos basada en webinarios

Métrica de entrenamiento	Valor
Horas de capacitación anuales por cliente	8.5 horas
Calificación de satisfacción del cliente	4.7/5.0

Asociaciones de investigación colaborativa

Neuroone mantiene colaboraciones de investigación estratégica con:

• 3 principales centros médicos académicos
• 2 Institutos de Investigación de Neurotecnología

Métrica de asociación de investigación	Valor
Subvenciones de investigación total	$ 1.2 millones en 2023
Documentos de investigación conjuntos publicados	7 publicaciones revisadas por pares

Consulta continua de rendimiento del producto

La compañía ofrece servicios de consulta de rendimiento dedicados con:

• Reuniones trimestrales de revisión de rendimiento
• Soporte de implementación de tecnología personalizada

Métrico de consulta	Valor
Horas de consulta por cliente	12 horas anualmente
Tarifa de cliente repetida	92%

Integración de comentarios de los clientes

Neuroone integra los comentarios de los clientes a través de:

• Encuestas de satisfacción trimestral
• Reuniones anuales de la junta asesora de clientes

Métrico de retroalimentación	Valor
Tasa de respuesta de la encuesta	68%
Mejoras de productos implementadas	14 Basado en sugerencias de clientes

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negocios: canales

Equipo directo de ventas de dispositivos médicos

A partir de 2024, Neuroone Medical Technologies Corporation mantiene un equipo de ventas dedicado centrado en dispositivos médicos neurológicos. El equipo de ventas consta de 12 representantes de ventas directas dirigidas a profesionales médicos neuroquirúrgicos y neurológicos.

Métrica del equipo de ventas	2024 datos
Representantes de ventas directas totales	12
Cobertura geográfica	Estados Unidos
Interacción promedio de ventas por mes	48

Presentaciones de conferencia médica y feria comercial

Neuroone participa activamente en conferencias de tecnología médica para mostrar sus tecnologías de dispositivos neurológicos.

• Conferencias anuales de tecnología médica a la que asistieron: 6
• Presentaciones totales de conferencia en 2024: 9
• Conferencias estimadas de alcance: 3,500 profesionales médicos

Plataformas de tecnología médica en línea

La compañía utiliza plataformas digitales para comunicar información del producto e interactuar con profesionales médicos.

Plataforma en línea	2024 Métricas de compromiso
Sitio web de la empresa	52,000 visitantes mensuales
Red profesional de LinkedIn	8.700 seguidores
Portales web de tecnología médica	4 listados de plataforma activa

Distribuidores de equipos médicos estratégicos

Neuroone colabora con distribuidores estratégicos de equipos médicos para expandir el alcance del mercado.

• Distribuidores estratégicos totales: 7
• Cobertura de la red de distribución: 38 estados
• Ingresos anuales de distribución: $ 4.2 millones

Marketing digital y publicidad médica

La compañía emplea estrategias de marketing digital específicas y publicidad médica para llegar a clientes potenciales.

Canal de marketing	2024 métricas
Presupuesto de publicidad digital	$620,000
Anuncios de publicación médica	12 ubicaciones trimestrales
Tasa de conversión de marketing digital	2.4%

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negocio: segmentos de clientes

Neurocirujanos y especialistas neurológicos

Mercado total direccionable de neurocirujanos en Estados Unidos: 4,356 profesionales en ejercicio a partir de 2023.

Tipo especializado	Número de profesionales	Penetración potencial del mercado
Neurocirujanos pediátricos	637	18.2%
Neurocirujanos adultos	3,719	81.8%

Hospitales y centros quirúrgicos

Número total de instalaciones de salud potenciales: 6,129 en todo el país.

• Centros quirúrgicos neurológicos: 1.247
• Centros de accidente cerebrovascular integrales: 389
• Centros médicos académicos: 142

Instituciones de investigación médica académica

Instituciones de investigación participadas activamente en el desarrollo de la tecnología neurológica: 87

Tipo de institución	Número de instituciones
Universidades de investigación de primer nivel	37
Centros de investigación de neurociencia especializados	50

Instalaciones de tratamiento neurológico

Total de instalaciones de tratamiento neurológico especializado: 2,563

• Centros de tratamiento de epilepsia: 412
• Clínicas de trastorno del movimiento: 276
• Centros de neuromodulación: 189

Adoptores de tecnología médica intervencionista

Análisis del segmento de adopción temprana para tecnologías neurológicas avanzadas.

Categoría de adopción de tecnología	Porcentaje de mercado
Innovadores	2.5%
Primeros usuarios	13.5%
Mayoría temprana	34%

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Neuroone Medical Technologies Corporation reportó gastos de I + D de $ 5,6 millones, lo que representa una inversión significativa en innovación tecnológica.

Año fiscal	Gastos de I + D	Porcentaje de ingresos totales
2023	$ 5.6 millones	68.3%
2022	$ 4.9 millones	62.7%

Costos de ensayo clínico y cumplimiento regulatorio

Los gastos de ensayos regulatorios y clínicos para 2023 totalizaron aproximadamente $ 3.2 millones, cubriendo las presentaciones de la FDA y los estudios clínicos en curso.

• Costos de envío de la FDA 510 (k): $ 250,000
• Gestión del ensayo clínico: $ 2.1 millones
• Documentación de cumplimiento regulatorio: $ 850,000

Inversiones de fabricación y producción

Neuroone invirtió $ 2.7 millones en infraestructura de fabricación y capacidades de producción en 2023.

Categoría de costos de fabricación	Gastos
Adquisición de equipos	$ 1.5 millones
Actualizaciones de la instalación de producción	$850,000
Gestión de la cadena de suministro	$350,000

Gastos de ventas y marketing

Los gastos de ventas y marketing para 2023 fueron de $ 1.8 millones, centrados en la penetración del mercado de dispositivos médicos.

• Marketing digital: $ 450,000
• Participación de la conferencia médica: $ 350,000
• Compensación del equipo de ventas: $ 1 millón

Protección y mantenimiento de la propiedad intelectual

Neuroone asignó $ 480,000 para protección de propiedad intelectual en 2023.

Categoría de protección de IP	Gastos
Potente y mantenimiento	$280,000
Consulta legal	$200,000

Neuroone Medical Technologies Corporation (NMTC) - Modelo de negocios: flujos de ingresos

Venta de dispositivos médicos

Para el año fiscal 2023, Neuroone Medical Technologies Corporation reportó ingresos totales de $ 1.47 millones, derivados principalmente de las ventas de dispositivos médicos de su tecnología de electrodos corticales EVO.

Producto	Ingresos (2023)	Segmento de mercado
Electrodo Cortical EVO	$ 1.47 millones	Monitoreo neurológico

Licencias de tecnología de monitoreo neural

Neuroone ha establecido acuerdos de licencia para su plataforma de monitoreo neural.

• Ingresos de licencia para 2023: $ 350,000
• Número de asociaciones de licencias activas: 3

Servicios de consultoría y capacitación

La compañía ofrece servicios de consultoría especializados relacionados con tecnologías de monitoreo neuronal.

Tipo de servicio	Ingresos anuales	Base de clientes
Consultoría técnica	$250,000	12 instituciones médicas
Programas de capacitación	$150,000	8 centros de investigación

Acuerdos de colaboración de investigación

Neuroone mantiene asociaciones de investigación con instituciones de investigación académica y médica.

• Financiación total de colaboración de investigación en 2023: $ 500,000
• Número de asociaciones de investigación activa: 5

Ingresos potenciales de regalías de las carteras de patentes

La compañía posee múltiples patentes en tecnología de monitoreo neuronal.

Categoría de patente	Patentes totales	Ingresos de regalías potenciales estimados
Tecnología de monitoreo neural	12 patentes activas	$ 175,000 regalías anuales proyectadas

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Value Propositions

You're looking at the core value NeuroOne Medical Technologies Corporation (NMTC) is delivering right now, late in 2025. It's all about making complex neurological procedures less invasive and more effective, and now expanding that core platform into chronic pain management.

Minimally Invasive Diagnostics: The foundation of the value proposition rests on high-definition sEEG (stereo-electroencephalography) electrodes designed for less invasive monitoring in epilepsy patients. This approach aims to improve the diagnostic phase of care compared to more traditional, potentially more invasive methods.

• Platform supports EEG recording, monitoring, ablation, drug delivery, and stimulation solutions.
• The technology is being developed for disorders like epilepsy, Parkinson's disease, dystonia, and essential tremors.

Single-System Solution: The OneRF™ Ablation system offers a unique advantage in the epilepsy space. It is the first and only device to receive FDA 510(k) clearance that combines both diagnostic and therapeutic applications within a single sEEG electrode. This capability allows for at-the-bedside ablation, which enhances versatility and convenience by avoiding separate procedures in different clinical settings. The technology provides monitoring, mapping, and ablation all in one system. This unique combination is a key differentiator for neurosurgeons using the platform.

Expanded Treatment Options: NeuroOne Medical Technologies Corporation expanded its platform significantly in August 2025 by receiving FDA 510(k) clearance for the OneRF® Trigeminal Nerve Ablation System. This system is designed to treat trigeminal neuralgia, a chronic facial pain condition. The target market is substantial, affecting approximately 150,000 people in the United States annually. The company is targeting a limited commercial launch for this pain management application in the fourth quarter of calendar 2025. This clearance leverages the existing OneRF® RF generator platform, marking the first step into broader pain management therapies beyond neurosurgery.

Improved Patient Outcomes: Clinical validation supports the efficacy of the OneRF® Ablation System in epilepsy treatment. For example, an early patient treated in June 2024, Clara, successfully surpassed the one year milestone of being seizure-free. Prior to treatment with the OneRF® platform, Clara was experiencing up to 10 seizures daily. Generally, the technology has demonstrated seizure reduction or complete seizure freedom for most patients that have received an ablation with the OneRF System. This translates directly into improved quality of life, allowing patients like Clara to enroll in college full-time and participate in previously hindered activities.

Here's a quick look at the financial performance supporting this commercialization effort as of late 2025. The preliminary unaudited product revenue for fiscal year 2025 reached a record $9.1 million, representing a 163% growth from the previous year. The company is debt-free and anticipates being fully funded through at least fiscal year 2026 following an $8.2 million capital raise in April 2025.

Metric	Value (As of Late 2025 Data)	Context/Period
FY 2025 Preliminary Product Revenue	$9.1 million	Fiscal Year 2025 (Preliminary, as of Oct 2025)
Product Revenue Growth (YoY FY2025 Guidance)	132% to 190% increase	Compared to FY 2024 Product Revenue of $3.5 million
Product Revenue (First Half FY 2025)	$4.7 million	97% increase YoY
Product Gross Margin (First Half FY 2025)	57.9%	Up from 27.9% in prior year period
Cash and Cash Equivalents	$6.6 million	As of September 30, 2025
Trigeminal Neuralgia Patient Population (US Annual)	Approximately 150,000	Target Market Size
OneRF Trigeminal Launch Target	Fourth Quarter of 2025	Limited Commercial Launch

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Customer Relationships

You're looking at how NeuroOne Medical Technologies Corporation (NMTC) manages its connections with the people who buy and use its technology. It's a mix of heavy-hitting partnerships and direct clinical engagement, which is typical when you're selling specialized medical devices.

Partner-managed relationship with Zimmer Biomet handling end-user sales

The relationship with Zimmer Biomet is central to getting the OneRF™ Ablation System into operating rooms. This is a classic distribution channel relationship, where a smaller innovator relies on a giant for scale. Zimmer Biomet, one of the largest global medical device companies in The United States, handles the commercialization exclusively across the U.S. and select international markets. This partnership kicked off with a significant financial component, as NeuroOne Medical Technologies Corporation received a $3.0 million upfront license payment in November 2024, which helped strengthen the balance sheet, leaving the company with no debt outstanding as of December 31, 2024.

The sales performance under this channel shows clear acceleration. For fiscal year 2024, product revenue was $3.5 million. The initial stocking orders with Zimmer Biomet were completed in the first quarter of fiscal 2025, where product revenue hit $3.3 million, a 235% increase year-over-year. The company is reiterating its full fiscal year 2025 product revenue guidance between $8.0 million and $10.0 million, representing a projected growth of 132% to 190% over fiscal year 2024. As of the third quarter of fiscal 2025, preliminary unaudited product revenue reached $9.1 million, showing 163% growth from the previous year.

This partnership also drives margin improvement. Product gross margin for fiscal year 2024 was 31%. For fiscal year 2025, the expectation is for product gross margins to range between 50% and 53%, up from the previous guidance of 47% to 51%. This compares favorably to the Q1 FY2025 product gross margin of 58.9%.

Here's a quick look at the financial impact of the Zimmer Biomet relationship:

Metric	FY 2024 Actual	FY 2025 Guidance (Reiterated Q3)	Q1 FY2025 Actual
Product Revenue (USD)	$3.5 million	$8.0 million to $10.0 million	$3.3 million
Product Gross Margin (%)	31%	50% to 53%	58.9%
Upfront License Payment (USD)	N/A	N/A	$3.0 million

Clinical support and training for neurosurgeons and hospital staff

The relationship extends beyond just delivery; it requires deep clinical integration. The OneRF ablation system is the first and only FDA-cleared product that uses the same sEEG electrode for both diagnostic and therapeutic applications in the brain. Clinical success is a key driver of adoption, with the majority of patients treated to date now being seizure free, and one patient reported seizure free for almost an entire year as of May 2025. Furthermore, a new ICD-10-PCS code for the 1RF ablation procedure became effective on October 1, 2024, which directly helps hospitals accurately report and process reimbursement claims.

NeuroOne Medical Technologies Corporation is focused on expanding the utility of its platform, which involves educating the clinical community:

• The OneRF ablation system is commercially available and treating epilepsy patients.
• The company has 3 FDA 510(k) cleared products for use in the brain.
• The company is planning additional submissions in 2025.

Direct engagement with key opinion leaders (KOLs) for clinical validation

Direct engagement with leading physicians is crucial for clinical validation and market acceptance. NeuroOne Medical Technologies Corporation utilizes discussions with neurosurgeon advisers who participated in their advisory board for brain ablation. This engagement is targeted toward expanding into new indications, such as trigeminal neuralgia, which affects roughly 150,000 people in the U.S. annually. The company was on track to submit its trigeminal nerve RF ablation 510(k) in the first half of 2025.

The broader medical affairs landscape shows that KOLs are increasingly relying on digital channels for knowledge. Proprietary research suggests that 54% of scientific knowledge gained by KOLs now stems from nonpersonal sources. This context shapes how NeuroOne Medical Technologies Corporation must approach its direct engagement strategy, balancing personal interactions with digital knowledge dissemination.

Investor relations and corporate updates for public shareholders

Maintaining transparency with public shareholders is a continuous effort, especially for a company that reported an EBITDA of -$11.64 million in the last twelve months (as of January 2025). The company communicates through formal filings and direct letters. A Letter to Shareholders was released on January 14, 2025, and an Investor Presentation was issued on May 13, 2025. A Virtual Investor Webinar was held on October 7, 2025.

Financially, the company bolstered its position by completing an oversubscribed capital raise in April 2025, totaling $8.2 million in net proceeds from institutional investors, which they believe funds the company through at least fiscal 2026. As of September 30, 2025, cash and cash equivalents stood at $6.6 million.

The ownership structure reflects significant retail investor interest:

• Share price as of November 21, 2025, was $0.64 / share.
• Approximately 61.30% of the stock is held by Public Companies and Individual Investors (retail).
• Institutional investors hold approximately 27.27% of the stock.
• There are 44 institutional owners and shareholders on record, holding a total of 14,703,530 shares.

Finance: draft 13-week cash view by Friday.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Channels

You're looking at how NeuroOne Medical Technologies Corporation (NMTC) gets its OneRF® technology into the hands of surgeons and hospitals as of late 2025. The strategy heavily leans on a major established partner, but they're also pushing for direct market access with new indications.

Zimmer Biomet's established global sales and distribution network.

This partnership is the backbone for broad market reach. The expanded exclusive distribution agreement with Zimmer Biomet, one of the world's largest medical device manufacturers, is key to scaling up. This channel was immediately monetized; NMTC received a $3.0 million upfront payment from Zimmer Biomet, which was recognized in the first quarter of fiscal year 2025. This deal covers the exclusive commercialization of the OneRF™ Ablation System across U.S. and international markets, leveraging Zimmer Biomet's extensive channels.

Direct sales team for strategic accounts and partnership management.

While Zimmer Biomet handles much of the volume, a direct sales presence is necessary for managing the relationship and securing strategic accounts. This team also focuses on new product lines, like the recently cleared OneRF® Trigeminal Nerve Ablation System, where they continue ongoing discussions with strategic partners who may also use the existing OneRF® brain ablation system.

Medical conferences and trade shows for product awareness and training.

Product awareness and training rely on direct engagement at industry events. This channel is critical for educating the surgical community on the differentiated features of the OneRF® technology, such as the multi-contact RF probe that allows for both precise localization and tailored ablation under temperature-controlled conditions.

Regulatory submissions (e.g., FDA 510(k)) to enable market access.

Market access is gated by regulatory success, and NMTC has been hitting milestones. The company already had three product families that achieved FDA 510(k) clearance before the newest indication. The OneRF® Trigeminal Nerve Ablation System received U.S. Food and Drug Administration ("FDA") clearance on August 18, 2025, after the submission was completed in May 2025. This clearance targets the trigeminal neuralgia market, which is expected to grow from $262 million in 2024 to over $416 million by 2030. The company targeted a limited commercial launch for this new system in the fourth quarter of calendar year 2025.

Here's the quick math on how the channel performance is translating into financial results for the fiscal year 2025 guidance and Q1 actuals:

Metric	FY 2024 Actual	Q1 FY 2025 Actual	FY 2025 Guidance	FY 2025 Preliminary (as of Oct 2025)
Product Revenue (Millions USD)	$3.5	$3.3	$8.0 - $10.0	$9.1
Product Revenue YoY Growth	77% increase	235% increase (from $1.0M in Q1 2024)	132% - 190% increase	163% growth
Product Gross Margin	31%	58.9%	47% - 51%	N/A

The Q1 FY 2025 total revenue hit $6.3 million, which included that $3 million license payment from Zimmer Biomet. Still, the momentum from the core product sales is clear, with product revenue in Q1 reaching $3.3 million.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Customer Segments

You're looking at the core groups NeuroOne Medical Technologies Corporation (NMTC) serves to drive its revenue, which, as of late 2025, is showing significant acceleration.

Neurosurgeons and Epileptologists: These are the primary clinical users who directly interact with the technology in the operating room. They are the champions for the OneRF® Ablation System, which is the first and only FDA-cleared single-electrode solution capable of both diagnostic recording and therapeutic ablation for epilepsy procedures. The positive clinical outcomes are a key driver for adoption; for instance, the first patient treated with the OneRF® Ablation System reached the milestone of over one year of seizure freedom. These specialists are also the target audience for the newly FDA-cleared OneRF® Trigeminal Nerve Ablation System, which received clearance on August 18, 2025.

Hospitals and Medical Centers: These entities are the purchasers of the capital equipment and the recurring disposable electrodes. Their decision-making is influenced by the system's ability to offer a better methodology, potentially reducing hospital stays and the number of surgeries required for a patient. The commercial traction is evident in the financial results; NeuroOne Medical Technologies Corporation reported preliminary unaudited product revenue for the fiscal year 2025 reached a record $9.1 million, a 163% growth from the previous year. For the third quarter of fiscal year 2025, product revenue was $1.7 million, up 105% year-over-year. The improved operational efficiency is reflected in the product gross margin expanding to 53.9% in Q3 2025.

Patients with Neurological Disorders: This segment represents the ultimate beneficiaries, primarily those with epilepsy, but increasingly those with trigeminal neuralgia and chronic pain. The company is targeting multiple billion-dollar markets with its minimally invasive approach. For the trigeminal neuralgia indication, where the OneRF® Trigeminal Nerve Ablation System is aimed, the therapeutics market is projected to grow from $262 million in 2024 to $416 million by 2030. Overall, the global neuralgia treatment market is estimated to be valued at USD 2.57 Bn in 2025.

The customer base is segmented by the product application and the purchasing entity, which can be summarized as follows:

Customer Segment Type	Primary Application/Role	Relevant Financial/Statistical Data Point
Clinical Users (Surgeons/Epileptologists)	Primary users of sEEG and Ablation Systems	One patient treated with OneRF® system achieved one year seizure freedom
Institutional Purchasers (Hospitals/Centers)	Purchasers of capital equipment and disposables	FY2025 Product Revenue Guidance range: $8.0 million to $10.0 million
Patients (Epilepsy/Trigeminal Neuralgia)	End-users benefiting from improved outcomes	Trigeminal Neuralgia Therapeutics Market projected to reach $416 million by 2030
Strategic Partners	Licensing and co-development entities	Received $3.0 million upfront license payment in Q1 2025 from Zimmer Biomet

Strategic medical device partners for licensing and co-development: This segment is crucial for scaling beyond direct sales, especially for new indications. The company has an expanded exclusive distribution partnership with Zimmer Biomet Holdings (ZBH). This relationship provided a significant financial boost, including a $3 million upfront license payment in the first quarter of fiscal 2025. Furthermore, NeuroOne Medical Technologies Corporation received its first order for its sEEG-based drug delivery system from a large biopharmaceutical company for preclinical research, opening a completely new market avenue. The company's ability to fund operations into at least fiscal year 2026 was bolstered by an oversubscribed capital raise totaling $8.2 million in April 2025.

The company's current focus is on expanding its cleared product families-it had three FDA-cleared product families as of early 2025-and leveraging these platforms across new customer segments like trigeminal neuralgia, with potential revenue generation anticipated in late calendar year 2025 if cleared.

• The OneRF® Ablation System for epilepsy is driving the core product revenue growth.
• The OneRF® Trigeminal Nerve Ablation System targets a market segment valued at $255.09 million in 2024 globally.
• The company reported cash and cash equivalents of $6.6 million as of September 30, 2025.
• The management team is also advancing development for spinal cord stimulation and drug delivery technologies, seeking further partnerships.

Finance: draft 13-week cash view by Friday.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Cost Structure

You're looking at the costs NeuroOne Medical Technologies Corporation (NMTC) is managing as it scales its commercial efforts, and honestly, for a med-tech firm, the cost structure is heavily weighted toward future pipeline development and getting the current product into more hands.

High R&D expenses to fund pipeline development represent a necessary cash burn to secure future revenue drivers. For the first quarter of fiscal year 2025, Research & Development expense was reported at $1.2 million. This compares to $1.5 million in the same period of fiscal year 2024, showing a slight reduction in that specific quarter, though pipeline funding remains a core cost driver for the company's long-term value proposition. The ongoing work includes the 510(k) submission for the OneRF Trigeminal Nerve Ablation System, which carries associated development and submission costs.

Manufacturing and inventory costs for disposable electrodes are directly reflected in the product gross margin. Management has raised its full fiscal year 2025 guidance for product gross margin to range between 50% and 53%, up from the initial guidance of 47% to 51%. This margin improvement suggests increasing operating leverage and efficiency in manufacturing and inventory management as volumes rise. To give you a snapshot of the margin improvement trend, the product gross margin in Q1 FY2025 actually hit 58.9%, which is significantly higher than the 31% seen in fiscal year 2024.

Selling, General & Administrative (SG&A) expenses are a key component of operating costs. Specifically for Q1 FY2025, SG&A expense was $2.0 million, down from $2.2 million in Q1 FY2024. Looking at the first nine months of fiscal year 2025, total SG&A expense decreased 8% to $5.6 million compared to the prior year period. These costs cover commercialization activities, administrative overhead, and supporting the Zimmer Biomet distribution network.

To break down the total operating expenses for that key quarter, here's what the numbers looked like:

Expense Category	Q1 FY2025 Amount
Total Operating Expenses	$3.2 million
Research & Development Expense	$1.2 million
Selling, General & Administrative Expense	$2.0 million

The total operating expenses for Q1 FY2025 were $3.2 million, a decrease of 12% compared to $3.7 million in Q1 FY2024.

Regulatory compliance and patent maintenance costs are essential, though specific figures aren't always broken out separately in the top-line reports. These costs are embedded within the operating expenses, particularly R&D and SG&A, as NeuroOne Medical Technologies Corporation manages its intellectual property portfolio and seeks necessary clearances, such as the 510(k) submission for the trigeminal nerve ablation system.

• Ongoing costs support the existing OneRF Ablation system's regulatory status.
• Costs are incurred for new product submissions, like the trigeminal nerve system.
• Patent maintenance fees secure the company's core technology platform.

Finance: draft 13-week cash view by Friday.

NeuroOne Medical Technologies Corporation (NMTC) - Canvas Business Model: Revenue Streams

NeuroOne Medical Technologies Corporation (NMTC) revenue streams are primarily anchored in the sale of its medical devices and strategic partnership income.

The core product sales come from the OneRF™ Ablation System and the Evo sEEG electrodes, which are used for the surgical diagnosis and treatment of neurological disorders like epilepsy.

For the preliminary fiscal year 2025, the product revenue reached $9.1 million, representing a 163% year-over-year increase. This preliminary figure was within the initial full-year guidance range of $8.0 million to $10.0 million for product revenue.

A significant component of non-product revenue involves one-time license payments, such as the $3.0 million upfront payment received from Zimmer Biomet in relation to the expanded exclusive distribution agreement. The first quarter of fiscal year 2025 alone included this $3.0 million collaboration payment.

The Zimmer Biomet distribution agreement also creates a stream for potential future milestone payments, contingent upon the achievement of certain performance criteria.

Here's a quick look at some of the key revenue and guidance figures for the period:

Metric	Amount/Range	Period/Context
Preliminary FY2025 Product Revenue	$9.1 million	Fiscal Year 2025 (Preliminary)
FY2025 Product Revenue YoY Growth	163%	Compared to prior year
FY2025 Product Revenue Guidance Range	$8.0 million to $10.0 million	Fiscal Year 2025 Guidance
FY2025 Product Gross Margin Guidance Range	47% to 51%	Fiscal Year 2025 Guidance
License Revenue Recognized (YTD)	$3.0 million	First Nine Months of FY2025
Product Revenue (9 Months FY2025)	$6.4 million	First Nine Months of FY2025

The revenue streams can be broken down by source type:

• Product sales from the OneRF™ Ablation System and Evo sEEG electrodes.
• One-time license payments, like the $3.0 million received from Zimmer Biomet.
• Potential future milestone payments from the Zimmer Biomet distribution agreement.

To give you a sense of the growth trajectory, product revenue for the first six months of fiscal 2025 totaled $4.7 million, up from $2.4 million in the same period of 2024.

The company also reported cash and cash equivalents of $6.6 million as of September 30, 2025.

Finance: draft 13-week cash view by Friday.